8th Eurasian Hematology Oncology Summit
2021 Updates on MRD in CLL: Chemoimmunotherapy vs. Targeted Approach; IGHV & TP53 Mutations
By
8th Eurasian Hematology Oncology Summit
FEATURING
Robin Foa
By
8th Eurasian Hematology Oncology Summit
FEATURING
Robin Foa
Login to view comments.
Click here to Login